Aprea Therapeutics, Inc.Aprea Therapeutics, Inc.Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪30.35 M‬USD
−3.32USD
‪−14.29 M‬USD
‪583.23 K‬USD
‪4.78 M‬
Beta (1Y)
1.63

About Aprea Therapeutics, Inc.

CEO
Oren Gilad
Headquarters
Doylestown
Website
Employees (FY)
7
Founded
2002
FIGI
BBG00Q6Q3K37
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of APRE is 5.27 USD — it has decreased by 5.72% in the past 24 hours. Watch Aprea Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aprea Therapeutics, Inc. stocks are traded under the ticker APRE.
APRE stock has fallen by 3.83% compared to the previous week, the month change is a 7.71% fall, over the last year Aprea Therapeutics, Inc. has showed a 35.82% increase.
We've gathered analysts' opinions on Aprea Therapeutics, Inc. future price: according to them, APRE price has a max estimate of 20.00 USD and a min estimate of 11.00 USD. Watch APRE chart and read a more detailed Aprea Therapeutics, Inc. stock forecast: see what analysts think of Aprea Therapeutics, Inc. and suggest that you do with its stocks.
APRE reached its all-time high on Dec 30, 2019 with the price of 1062.20 USD, and its all-time low was 2.78 USD and was reached on Jul 7, 2023. View more price dynamics on APRE chart.
See other stocks reaching their highest and lowest prices.
APRE stock is 10.06% volatile and has beta coefficient of 1.63. Track Aprea Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aprea Therapeutics, Inc. there?
Today Aprea Therapeutics, Inc. has the market capitalization of ‪30.35 M‬, it has increased by 5.23% over the last week.
Yes, you can track Aprea Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aprea Therapeutics, Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
APRE earnings for the last quarter are −0.67 USD per share, whereas the estimation was −0.76 USD resulting in a 11.84% surprise. The estimated earnings for the next quarter are −0.60 USD per share. See more details about Aprea Therapeutics, Inc. earnings.
Aprea Therapeutics, Inc. revenue for the last quarter amounts to ‪380.57 K‬ USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪50.00 K‬ USD.
APRE net income for the last quarter is ‪−2.81 M‬ USD, while the quarter before that showed ‪−3.44 M‬ USD of net income which accounts for 18.39% change. Track more Aprea Therapeutics, Inc. financial stats to get the full picture.
No, APRE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 18, 2024, the company has 7.00 employees. See our rating of the largest employees — is Aprea Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aprea Therapeutics, Inc. EBITDA is ‪−13.99 M‬ USD, and current EBITDA margin is ‪−2.65 K‬%. See more stats in Aprea Therapeutics, Inc. financial statements.
Like other stocks, APRE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aprea Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aprea Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aprea Therapeutics, Inc. stock shows the sell signal. See more of Aprea Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.